Under a previously announced collaboration agreement between Raptor and University of California, San Diego (UCSD) to evaluate the safety and potential efficacy of cysteamine in non-alcoholic steatohepatitis (NASH)
According to the company, the new model is designed to be more effective at driving sales growth by better meeting the diverse needs of multiple customers as well
The molecular diagnostics business will operate under the name Myriad Genetics, Inc and the research and drug development businesses will operate under the name Myriad Pharmaceuticals, Inc. The
This move is said to be part of Nanosyn’s strategy to become a worldwide leader in drug discovery services and reflects the company’s evolution from a small regional
This new research agreement is the second collaboration agreement signed between Genentech and Nerviano Medical Sciences (NMS) in less than 12 months. Terms of the multi-year collaboration include
Dr Sorensen is currently board director, president and CEO of Ascenta Therapeutics. Dr Sorensen is an experienced leader and administrator in cancer therapeutics and cancer drug development. John
The trial is designed to evaluate the safety, tolerability and pharmacokinetics of NGX426 when given once daily for five consecutive days. NGX426 has been safely administered to more
The Mirasol pathogen reduction technology system (PRT) system is a proprietary technology that uses riboflavin and UV light to reduce the levels of infectious pathogens and inactivate white
The company believes that it can address the issues raised by the FDA in its complete response letter in a timely manner without conducting any additional clinical trials
The primary objective of the Phase I dose escalation study is to determine the safety, maximum tolerated dose and objective response rate of GRN163L when administered intravenously in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.